Selected article for: "future research and respiratory infection"

Author: Liu, Shao; Tang, Mi-Mi; Du, Jie; Gong, Zhi-Cheng; Sun, Shu-Sen
Title: COVID-19 in gastroenterology and hepatology: Lessons learned and questions to be answered
  • Cord-id: d73fd4jt
  • Document date: 2021_6_16
  • ID: d73fd4jt
    Snippet: BACKGROUND: Although coronavirus disease 2019 (COVID-19) presents primarily as a lower respiratory tract infection, increasing data suggests multiorgan, including the gastrointestinal (GI) tract and liver, involvement in patients who are infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). AIM: To provide a comprehensive overview of COVID-19 in gastroenterology and hepatology. METHODS: Relevant studies on COVID-19 related to the study aim were undertaken through a literature
    Document: BACKGROUND: Although coronavirus disease 2019 (COVID-19) presents primarily as a lower respiratory tract infection, increasing data suggests multiorgan, including the gastrointestinal (GI) tract and liver, involvement in patients who are infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). AIM: To provide a comprehensive overview of COVID-19 in gastroenterology and hepatology. METHODS: Relevant studies on COVID-19 related to the study aim were undertaken through a literature search to synthesize the extracted data. RESULTS: We found that digestive symptoms and liver injury are not uncommon in patients with COVID-19 and varies in different individuals. The most common GI symptoms reported are diarrhea, nausea, vomiting, and abdominal discomfort. Other atypical GI symptoms, such as loss of smell and taste and GI bleeding, have also been reported along with the evolvement of COVID-19. Liver chemistry abnormalities mainly include elevation of aspartate transferase, alanine transferase, and total bilirubin. It is postulated to be related to the binding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus to the angiotensin converting enzyme-2 receptor located on several different human cells. CONCLUSION: Standardized criteria should be established for diagnosis and grading of the severity of GI symptoms in COVID-19 patients. Gastroenterology and hepatology in special populations, such as children and elderly, should be the focus of further research. Future long-term data regarding GI symptoms should not be overlooked.

    Search related documents:
    Co phrase search for related documents
    • abdominal discomfort and liver disease: 1
    • abdominal discomfort and liver function: 1
    • abdominal pain and abnormal level: 1, 2, 3, 4
    • abdominal pain and abnormal liver: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • abdominal pain and abnormal liver function: 1, 2, 3, 4, 5, 6
    • abdominal pain and absence presence: 1, 2, 3, 4, 5, 6
    • abdominal pain and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • abdominal pain and liver affect: 1, 2, 3, 4
    • abdominal pain and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and liver dysfunction: 1, 2, 3, 4
    • abdominal pain and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8
    • abdominal pain and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • abnormal ast level and liver dysfunction: 1
    • abnormal ast level and liver function: 1
    • abnormal level and absence presence: 1
    • abnormal level and acute respiratory distress syndrome: 1, 2
    • abnormal level and liver affect: 1
    • abnormal level and liver disease: 1, 2, 3
    • abnormal level and liver dysfunction: 1, 2